Moderna becomes the first company to have positive information about its SARS-COV2 vaccine published in a peer-reviewed journal. The New England Journal of Medicine published a preliminary report which has some positive information. As the R-0 of the virus continues to rise in this part of the Pandemic, many epidemiologists and virologists say that a widely distributed and effective vaccine is the only way to get back to some semblance of “normal”.

The NEJM article states:

After the first vaccination, antibody responses were higher with higher dose (day 29 enzyme-linked immunosorbent assay anti–S-2P antibody geometric mean titer [GMT], 40,227 in the 25-μg group, 109,209 in the 100-μg group, and 213,526 in the 250-μg group). After the second vaccination, the titers increased (day 57 GMT, 299,751, 782,719, and 1,192,154, respectively). After the second vaccination, serum-neutralizing activity was detected by two methods in all participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control convalescent serum specimens. Solicited adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Systemic adverse events were more common after the second vaccination, particularly with the highest dose, and three participants (21%) in the 250-μg dose group reported one or more severe adverse events.

Full text is available from the New England Journal of Medicine